Your Source for Venture Capital and Private Equity Financings

Volastra Therapeutics Scores $12M Seed Round

2021-04-06
NEW YORK, NY, Volastra Therapeutics today announced the extension of its original $12 million seed round to a total of $44 million.
Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, today announced the extension of its original $12 million seed round to a total of $44 million. New investors Vida Ventures and Catalio Capital Management joined a syndicate that includes Polaris Partners, Droia Ventures, ARCH Venture Partners and Quark Venture.

Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis, one of the major unsolved challenges in cancer treatment. Co-founders Lewis Cantley, Ph.D., Olivier Elemento, Ph.D. and Samuel Bakhoum, M.D., Ph.D., made seminal discoveries about the role of chromosomal instability in driving cancer spread. Volastra is built on those insights. Based in West Harlem, N.Y., Volastra is committed to improving outcomes for people living with cancer.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors